A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of BI 1810631 in the Blood
Status:
Completed
Trial end date:
2023-12-08
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to investigate the effect of multiple oral doses of the
strong CYP3A inducer carbamazepine on the pharmacokinetics of a single dose of BI 1810631 in
plasma.